"This class of medications was developed in the early 2000s to treat Type 2 Diabetes. Later, in 2019, it was approved for the treatment of obesity. Since that time, usage has soared a whopping 700 percent. At present, close to 12 percent - that's one person in eight - of Americans have used these new mediations."
"What the new weight loss drugs are not is a simple, one-stop solution to a complex and often lifelong challenge. There is no substitute for sound medical advice and a solid, evidence-based approach to weight loss and long-term weight management."
"According to a recently published Gallup National Health and Well-being Index, obesity rates in America have declined from 39.9 percent in 2022 to 37 percent in 2025, translating to approximately 7.6 million fewer people in America suffering from obesity."
GLP-1 and semaglutide weight loss medications, originally developed for Type 2 Diabetes treatment in the early 2000s, gained FDA approval for obesity treatment in 2019. Usage has increased 700 percent since approval, with approximately 12 percent of Americans now using these medications. Recent data shows obesity rates in America declined from 39.9 percent in 2022 to 37 percent in 2025, representing approximately 7.6 million fewer obese individuals. However, these medications are not quick fixes or miracle cures for the complex challenge of weight management. Understanding their benefits, risks, and side effects through evidence-based medical advice is essential for determining whether prescription weight loss medication is appropriate for individual circumstances.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]